Platt Donna M, Rodefer Joshua S, Rowlett James K, Spealman Roger D
New England Regional Primate Research Center, Harvard Medical School, One Pine Hill Drive, PO Box 9102, MA 01772-9102, Southborough, USA.
Psychopharmacology (Berl). 2003 Mar;166(3):298-305. doi: 10.1007/s00213-002-1347-0. Epub 2003 Feb 13.
The D2-like receptor partial agonist terguride has a profile of behavioral effects in rats that suggests potential benefit as a pharmacotherapy for cocaine addiction.
The present study investigated the effects of terguride on cocaine- and food-maintained behavior in squirrel monkeys.
Squirrel monkeys were trained to respond on a second-order schedule (FI 10 min, FR 10 or 30:S) of either i.v. cocaine injection or food pellet delivery. Additional monkeys were studied using quantitative observational techniques to construct side effect profiles. Under each procedure, the effects of terguride were compared with those of the reference D2-like receptor antagonist nemonapride and the D2-like receptor full agonist quinpirole.
Terguride and nemonapride, but not quinpirole, dose-dependently reduced cocaine-maintained behavior. In animals self-administering food, terguride decreased response rates at doses lower than those required to suppress cocaine-maintained behavior. Effective doses of terguride had no systematic effect on motor activity or muscle rigidity, whereas effective doses of nemonapride virtually eliminated motor activity and induced severe catalepsy. The primary observable effects of terguride were a modest increase in self-directed behavior (a D2-receptor agonist-like effect) at intermediate doses and a small increase in static posture (a D2-receptor antagonist-like effect) at the highest dose tested.
The results suggest that terguride has advantages over conventional D2-like receptor antagonists and agonists as a candidate pharmacotherapy for cocaine abuse; however, terguride significantly reduces food-maintained behavior at lower doses than those needed to decrease cocaine-maintained behavior suggesting limitations on the utility of terguride as a medication for cocaine addiction.
D2样受体部分激动剂替古瑞肽在大鼠身上具有一系列行为效应,表明其作为可卡因成瘾药物治疗可能具有潜在益处。
本研究调查了替古瑞肽对松鼠猴中由可卡因和食物维持的行为的影响。
训练松鼠猴按照静脉注射可卡因或递送食物颗粒的二阶程序(固定间隔10分钟,固定比率10或30:连续)做出反应。使用定量观察技术对另外的猴子进行研究以构建副作用概况。在每个程序下,将替古瑞肽的效应与参考D2样受体拮抗剂奈莫必利和D2样受体完全激动剂喹吡罗的效应进行比较。
替古瑞肽和奈莫必利,但不是喹吡罗,剂量依赖性地减少了由可卡因维持的行为。在自行摄取食物的动物中,替古瑞肽在低于抑制由可卡因维持行为所需的剂量下降低了反应率。替古瑞肽的有效剂量对运动活动或肌肉强直没有系统性影响,而奈莫必利的有效剂量几乎消除了运动活动并诱发了严重的僵住症。替古瑞肽的主要可观察到的效应是在中等剂量下自我导向行为适度增加(一种D2受体激动剂样效应),以及在测试的最高剂量下静态姿势略有增加(一种D2受体拮抗剂样效应)。
结果表明,作为可卡因滥用的候选药物治疗,替古瑞肽比传统的D2样受体拮抗剂和激动剂具有优势;然而,替古瑞肽在低于减少由可卡因维持行为所需的剂量下就显著降低了由食物维持的行为,这表明替古瑞肽作为可卡因成瘾药物的效用存在局限性。